去年在twitter看到的小道消息- 中国之所以不批准mRNA疫苗就是想以市场为要挟得到全套技术，今天被主流媒体证实了。 中国在2020和2021年向Moderna提出以全套转让mRNA技术，为进入中国市场的先决条件，被Moderna拒绝。 但是现在发达国家逐渐走出疫情，市场需求疲软，Moderna态度开始软化了。 https://www.ft.com/content/a481c129-c5aa-4972-84a8-3a45bb000098 Moderna has refused to hand over to China the core intellectual property behind the development of its breakthrough Covid-19 vaccine, leading to a collapse in negotiations on its sale there, according to multiple people familiar with the matter. The Massachusetts-based pharmaceutical company turned down Beijing’s request to hand over the recipe for its messenger RNA vaccine because of commercial and safety concerns, said two people involved in negotiations that took place between 2020 and 2021. The vaccine maker says it is still “eager” to sell the product to China. The mRNA vaccine technology used by Moderna and BioNTech/Pfizer provides longer-lasting and higher levels of protection than the inactivated vaccine technology used by Chinese makers. Several Chinese pharma companies are racing to develop a homemade mRNA alternative but have struggled with the emergence of more infectious variants. One individual close to the Moderna team in Greater China said the company had “given up” on its previous efforts to access the Chinese market, because of Beijing’s demand that it hand over the technology as a prerequisite for selling into the country. To date, Beijing has offered two routes for foreign Covid-19 vaccine makers to distribute in China, dependent on regulatory approval: carrying out a full technology transfer to a domestic drugmaker or establishing a manufacturing facility in China with a local partner, while keeping control of the underlying technology. Moderna was pressed to take the former option. The German group BioNTech has struck a deal with Shanghai Fosun Pharmaceutical to conduct clinical trials and commercialise its vaccine in 2020, which meant it retained control of the intellectual property. Under the partnership, Fosun agreed to provide a factory that would make up to 1bn doses a year. By contrast, the Shanghai-based Everest Medicines group made a deal to access the Canadian biotech company Providence Therapeutics’s mRNA vaccine candidate that involved a full tech transfer. Beijing has not granted either vaccine regulatory approval. The Moderna leadership did not want to hand over the vaccine recipe to a Chinese partner because of the reputational damage if the local partner botched the manufacturing, said two people with knowledge of the matter. Moderna has been fiercely protective of its intellectual property around the world, saying handing over patents would do little to address supply constraints. Talks in Italy for a tech transfer to local manufacturing sites have also failed, but Moderna gave the reason that it lacked the capacity to oversee it. China has not approved any mRNA products for therapeutic purposes, and the mass production of this kind of vaccine is more complex than China’s existing inactivated vaccines made by Sinopharm and Sinovac. In recent weeks, Moderna has signalled a willingness to restart talks with China. Its chief medical officer Paul Burton said this month: “We would certainly be very eager to collaborate with China if they felt that there was a need for a vaccine there.” Burton’s comments came days after US president Joe Biden proclaimed the “pandemic is over”, wiping more than $10bn off the market value of the main makers of vaccines, including Moderna. Moderna told the Financial Times: “We are not currently engaged in supply talks with China. We are open to speaking with countries on their supply needs for Covid-19 vaccines.” Industry insiders observed that the company’s willingness to reopen talks with China, the last remaining major economy without an mRNA jab, has been driven by sluggish demand for vaccines in the wealthier countries where it first targeted sales. According to Airfinity, a data firm that monitors vaccine shipments, Moderna has shipped a greater share of its vaccines to high-income countries than the other three major vaccine makers, a strategy that earned it billions of dollars in profit. More than 86 per cent of Moderna’s jabs have been delivered to high-income countries, compared with 74 per cent for BioNTech/Pfizer, 63 per cent for Johnson & Johnson and 19 per cent for AstraZeneca. S lowing demand has afflicted all the major coronavirus vaccine makers, but with the Covid-19 jab its only approved product, the pressure on Moderna’s management is particularly acute, according to people familiar with the matter.
中国在2020和2021年向Moderna提出以全套转让mRNA技术，为进入中国市场的先决条件，被Moderna拒绝。 但是现在发达国家逐渐走出疫情，市场需求疲软，Moderna态度开始软化了。
https://www.ft.com/content/a481c129-c5aa-4972-84a8-3a45bb000098
Moderna has refused to hand over to China the core intellectual property behind the development of its breakthrough Covid-19 vaccine, leading to a collapse in negotiations on its sale there, according to multiple people familiar with the matter.
The Massachusetts-based pharmaceutical company turned down Beijing’s request to hand over the recipe for its messenger RNA vaccine because of commercial and safety concerns, said two people involved in negotiations that took place between 2020 and 2021. The vaccine maker says it is still “eager” to sell the product to China.
The mRNA vaccine technology used by Moderna and BioNTech/Pfizer provides longer-lasting and higher levels of protection than the inactivated vaccine technology used by Chinese makers. Several Chinese pharma companies are racing to develop a homemade mRNA alternative but have struggled with the emergence of more infectious variants.
One individual close to the Moderna team in Greater China said the company had “given up” on its previous efforts to access the Chinese market, because of Beijing’s demand that it hand over the technology as a prerequisite for selling into the country.
To date, Beijing has offered two routes for foreign Covid-19 vaccine makers to distribute in China, dependent on regulatory approval: carrying out a full technology transfer to a domestic drugmaker or establishing a manufacturing facility in China with a local partner, while keeping control of the underlying technology. Moderna was pressed to take the former option.
The German group BioNTech has struck a deal with Shanghai Fosun Pharmaceutical to conduct clinical trials and commercialise its vaccine in 2020, which meant it retained control of the intellectual property. Under the partnership, Fosun agreed to provide a factory that would make up to 1bn doses a year. By contrast, the Shanghai-based Everest Medicines group made a deal to access the Canadian biotech company Providence Therapeutics’s mRNA vaccine candidate that involved a full tech transfer. Beijing has not granted either vaccine regulatory approval.
The Moderna leadership did not want to hand over the vaccine recipe to a Chinese partner because of the reputational damage if the local partner botched the manufacturing, said two people with knowledge of the matter.
Moderna has been fiercely protective of its intellectual property around the world, saying handing over patents would do little to address supply constraints. Talks in Italy for a tech transfer to local manufacturing sites have also failed, but Moderna gave the reason that it lacked the capacity to oversee it. China has not approved any mRNA products for therapeutic purposes, and the mass production of this kind of vaccine is more complex than China’s existing inactivated vaccines made by Sinopharm and Sinovac.
In recent weeks, Moderna has signalled a willingness to restart talks with China. Its chief medical officer Paul Burton said this month: “We would certainly be very eager to collaborate with China if they felt that there was a need for a vaccine there.” Burton’s comments came days after US president Joe Biden proclaimed the “pandemic is over”, wiping more than $10bn off the market value of the main makers of vaccines, including Moderna.
Moderna told the Financial Times: “We are not currently engaged in supply talks with China. We are open to speaking with countries on their supply needs for Covid-19 vaccines.” Industry insiders observed that the company’s willingness to reopen talks with China, the last remaining major economy without an mRNA jab, has been driven by sluggish demand for vaccines in the wealthier countries where it first targeted sales. According to Airfinity, a data firm that monitors vaccine shipments,
Moderna has shipped a greater share of its vaccines to high-income countries than the other three major vaccine makers, a strategy that earned it billions of dollars in profit. More than 86 per cent of Moderna’s jabs have been delivered to high-income countries, compared with 74 per cent for BioNTech/Pfizer, 63 per cent for Johnson & Johnson and 19 per cent for AstraZeneca. S
lowing demand has afflicted all the major coronavirus vaccine makers, but with the Covid-19 jab its only approved product, the pressure on Moderna’s management is particularly acute, according to people familiar with the matter.
以前MRNA吹嘘中和抗体是没活疫苗的10倍左右，挺唬人的，可惜在 OMICRON强大的感染力下，MRNA也没扛住这个感染，
现在大伙都是靠感染后的自身免疫力在抗击疫情
理想和现实，是卖家秀和买家秀的区别。
那是我还发帖说 mrna第一次做成疫苗未可知的副作用 被一群脑残追着骂 真是醉了
真是吹牛不脸红啊
印尼几乎批准了全世界所有的疫苗，跟过关需要护照里夹钱一样。
那是前年吧。去年已经被骂成筛子了。
中国到现在还傻x的到处搞封禁，就是对自己家的疫苗没有信心。
说明中国有自知之明
疫苗没用还不戴口罩不抗疫的才是傻x
哈哈哈
这个不光是要配方，是要整个全套制造工艺。
再加一条：高薪“聘请” 千人计划大家都懂
哪里的香港数据？卫生署公布的数据里三剂灭活疫苗的死亡率是三剂mRNA疫苗的五倍。
美国高科技移民什么意思。 高科技天上掉的？还不是靠人。 就美国现在崇尚嘴皮子的，没个移民，真是要堕落了。
我看大家记得更清楚的是你一边口吹灭活diss mRNA 一边带着你老爹蹭打mRNA, 要点脸很难吧LOL
市场换技术就是很正常的商业操作，双方商量好条件就没问题，你看微软和Google每年会购买兼并多少小的创新公司，他们怎么不自己去研发呢
坚持世界眼光、国际标准、中国特色、高点定位
我也是！认真工作为美国交税支持美国政府实实在在打击我共，同时网上嘴炮爱国，两下不矛盾！
微软和Google每年会购买兼并多少小的创新公司， 投资并购不是市场换技术。市场换技术是只有你共干的。因为假设是市场是被xx垄断的,不是开放的。开放的市场怎么会有市场换技术？
微软和Google能用行政命令控制哪国市场？
有区别吗，虽然形式不同，最后一样是钱说话，双方自愿
你没看具体数字吧？香港的老人不放心mRNA疫苗，大部分打的国产灭活，老人死亡率高有什么奇怪的？mRNA的最大优势是研发过程短，但时至今日，这个优点是不是真实的，仁者见仁吧。
中国市场不开放，资本家难道不比老百姓更清楚，Moderna当初没同意，这锤子买卖也没做成，现在欧美疫苗市场饱和了，卖不动了，立场又松动了，还不是为了追求金钱利润，要是为了坚持政治立场，就不要松动，继续不合作就行了。
说到底，就是极权政府可以用全体国民做人质，和资本家谈判～～
不算P用没有吧，就是omicron没用，之前的beta，delta还是多少有点用
omicron完全是天赐的疫苗，真是感叹于自然的力量。
天地不仁，以万物为刍狗
扯犊子， 说偷有证据就拿出来打脸。
你没看具体数字吧？70+组的死亡率也是灭活是mRNA的两倍。
是因为人家不转让技术就剥夺墙内屁民使用mRNA疫苗的权力。
这就是你在美国交税为美军添砖加瓦的原因吗？
哦，你是不交税的龙虾党啊？那没事了。
你说疫苗有用，而且是接近100防死亡那为什么美国Delta/omicron那两波的死亡数量还那么高？那两波的时候大部分人都打疫苗了。不是还说Delta/omicron的致死率低吗？
我就是Delta以后对疫苗的有效性产生了怀疑。之前只是怀疑他的安全性。